Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Documenti analoghi

• Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
  di: Emilio Iannitto, et al.
  Pubblicazione: (2024-03-01)
• Measuring the Unmeasurable
  Pubblicazione: (2026)
• Assessing Mobile BRISMA LMS in Flipped Classroom Models to Improve Student Performance: A Structural Equation Modeling Approach
  di: Mahdiyah Mahdiyah, et al.
  Pubblicazione: (2025-04-01)
• IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
  di: Maria Cristina Pirosa, et al.
  Pubblicazione: (2022-12-01)
• Measured, unmeasured, mismeasured, and unjustified pessimism
  di: Deirdre Nansen McCloskey
  Pubblicazione: (2014-12-01)